2.14
2.73%
-0.06
Akoya Biosciences Inc stock is traded at $2.14, with a volume of 135.02K.
It is down -2.73% in the last 24 hours and down -23.57% over the past month.
Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler (formerly CODEX) and PhenoImager (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.
See More
Previous Close:
$2.20
Open:
$2.21
24h Volume:
135.02K
Relative Volume:
0.89
Market Cap:
$109.04M
Revenue:
$96.63M
Net Income/Loss:
$-63.32M
P/E Ratio:
-1.0863
EPS:
-1.97
Net Cash Flow:
$-54.55M
1W Performance:
-0.93%
1M Performance:
-23.57%
6M Performance:
+8.91%
1Y Performance:
-52.97%
Akoya Biosciences Inc Stock (AKYA) Company Profile
Name
Akoya Biosciences Inc
Sector
Industry
Phone
855.896.8401
Address
100 CAMPUS DRIVE, MARLBOROUGH
Compare AKYA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
AKYA
Akoya Biosciences Inc
|
2.14 | 109.04M | 96.63M | -63.32M | -54.55M | -1.97 |
ISRG
Intuitive Surgical Inc
|
538.55 | 192.83B | 7.87B | 2.24B | 586.00M | 4.25 |
BDX
Becton Dickinson Co
|
221.98 | 64.77B | 20.18B | 1.73B | 3.07B | 5.51 |
ALC
Alcon Inc
|
88.23 | 43.75B | 9.76B | 1.16B | 665.00M | 0.72 |
RMD
Resmed Inc
|
249.33 | 36.84B | 4.81B | 1.11B | 1.35B | 6.16 |
WST
West Pharmaceutical Services Inc
|
323.32 | 23.33B | 2.88B | 499.60M | 321.60M | 7.41 |
Akoya Biosciences Inc Stock (AKYA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-15-24 | Downgrade | Craig Hallum | Buy → Hold |
Aug-06-24 | Downgrade | BTIG Research | Buy → Neutral |
Aug-06-24 | Downgrade | JP Morgan | Overweight → Neutral |
Aug-06-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jun-21-24 | Initiated | Craig Hallum | Buy |
Dec-14-23 | Initiated | Guggenheim | Neutral |
Jul-05-23 | Resumed | JP Morgan | Overweight |
Feb-02-23 | Initiated | UBS | Buy |
Nov-03-22 | Initiated | CapitalOne | Overweight |
Oct-06-22 | Initiated | Stephens | Overweight |
Jun-22-22 | Initiated | BTIG Research | Buy |
Jan-06-22 | Resumed | Piper Sandler | Overweight |
May-11-21 | Initiated | Canaccord Genuity | Buy |
May-11-21 | Initiated | JP Morgan | Overweight |
May-11-21 | Initiated | Morgan Stanley | Overweight |
May-11-21 | Initiated | Piper Sandler | Overweight |
View All
Akoya Biosciences Inc Stock (AKYA) Latest News
Piper Sandler Reiterates “Overweight” Rating for Akoya Biosciences (NASDAQ:AKYA) - Defense World
Akoya Biosciences stock target cut, rating held on recent earnings report - Investing.com Canada
Akoya Biosciences' (AKYA) Overweight Rating Reiterated at Piper Sandler - MarketBeat
Revenue Downgrade: Here's What Analysts Forecast For Akoya Biosciences, Inc. (NASDAQ:AKYA) - Simply Wall St
Time To Worry? Analysts Just Downgraded Their Akoya Biosciences, Inc. (NASDAQ:AKYA) Outlook - Yahoo Finance
Canaccord Genuity Group Issues Pessimistic Forecast for Akoya Biosciences (NASDAQ:AKYA) Stock Price - Defense World
Akoya Biosciences Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St
Akoya Biosciences shares target cut, maintains buy rating on Q3 results - Investing.com
Craig-Hallum Downgrades Akoya Biosciences (AKYA) - MSN
Akoya stock plunges 30% on outlook as Craig-Hallum cuts to hold - MSN
Akoya stock plunges 30% on outlook as Craig-Hallum cuts to hold (NASDAQ:AKYA) - Seeking Alpha
Akoya Biosciences (NASDAQ:AKYA) Price Target Cut to $3.50 by Analysts at Canaccord Genuity Group - MarketBeat
Akoya Biosciences (NASDAQ:AKYA) Stock Rating Lowered by Craig Hallum - MarketBeat
Akoya Biosciences, Inc. (NASDAQ:AKYA) Q3 2024 Earnings Call Transcript - Insider Monkey
Akoya Biosciences Shares Sink After FY24 Outlook Cut - MarketWatch
Akoya Biosciences, Inc. (NASDAQ:AKYA) Short Interest Down 20.8% in October - MarketBeat
Akoya Biosciences, Inc. Revises Earnings Guidance for the Full Year 2024 - Marketscreener.com
Akoya: Q3 Earnings Snapshot - Darien Times
Akoya Biosciences Reports Q3 2024 Financial Results - TipRanks
Akoya Biosciences (AKYA) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Akoya Biosciences Reports Third Quarter 2024 Financial Results - GlobeNewswire
Akoya Biosciences earnings missed, revenue fell short of estimates By Investing.com - Investing.com Nigeria
Akoya Biosciences Inc (AKYA) Q3 2024 Earnings Report Preview: What To Look For - Yahoo Finance
Is Akoya Biosciences (NASDAQ:AKYA) Using Too Much Debt? - Simply Wall St
Akoya Biosciences, Inc. (NASDAQ:AKYA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Akoya Biosciences (AKYA) Set to Announce Quarterly Earnings on Thursday - MarketBeat
Precision for Medicine to Offer Spatial Biology Solutions Incorporating the PhenoCycler®-Fusion 2.0 System and the new Phenocode™ Discovery IO60 Panel from Akoya Biosciences - PR Newswire
Akoya Biosciences Unveils a New Era in Spatial Content - GlobeNewswire
Akoya Biosciences Unveils a New Era in Spatial Content Innovation with the PhenoCode™ Discovery IO60 and Mouse FFPE IO Panel - Yahoo Finance
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Akoya Biosciences, Inc. (NASDAQ:AKYA) Sees Significant Decrease in Short Interest - MarketBeat
Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024 - StockTitan
BTIG Downgrades Akoya Biosciences (AKYA) - MSN
Akoya Biosciences, Inc. (NASDAQ:AKYA) Receives $6.56 Consensus Price Target from Brokerages - MarketBeat
Akoya Biosciences (AKYA) Stock Price, News & Analysis - MarketBeat
Akoya Biosciences Inc (AKYA) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
Akoya Biosciences, Inc. (NASDAQ:AKYA) Stock Rockets 36% But Many Are Still Ignoring The Company - Simply Wall St
Akoya Biosciences joins UK cancer research initiative By Investing.com - Investing.com South Africa
Akoya Biosciences joins UK cancer research initiative - Investing.com India
Akoya’s Leading Spatial Proteomics Platforms Selected for - GlobeNewswire
Akoya's Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer Immunotherapy - The Manila Times
Akoya's Leading Spatial Proteomics Platforms Selected for Use by Uk-Based Manifest Consortium to Revolutionize Cancer Immunotherapy - Marketscreener.com
IPO Alert: Akoya Biosciences - RTTNews
Akoya Biosciences appoints new chairman By Investing.com - Investing.com South Africa
Akoya Biosciences Appoints Scott Mendel as Chairman of the Board of Directors - citybiz
Akoya Biosciences Announces Scott Mendel as Chairman of the Board of Directors - ForexTV.com
Akoya Biosciences appoints new chairman - Investing.com
Akoya Biosciences Inc Stock (AKYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Akoya Biosciences Inc Stock (AKYA) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
McKelligon Brian | President and CEO |
Jun 11 '24 |
Sale |
2.08 |
7,500 |
15,630 |
224,733 |
McKelligon Brian | President and CEO |
Jun 06 '24 |
Option Exercise |
0.30 |
7,500 |
2,272 |
232,233 |
McKelligon Brian | President and CEO |
Jun 06 '24 |
Sale |
2.01 |
7,500 |
15,064 |
224,733 |
McKelligon Brian | President and CEO |
Mar 20 '24 |
Option Exercise |
0.30 |
7,500 |
2,272 |
239,368 |
McKelligon Brian | President and CEO |
Mar 20 '24 |
Sale |
4.97 |
7,500 |
37,243 |
231,868 |
McKelligon Brian | President and CEO |
Mar 13 '24 |
Sale |
4.94 |
7,500 |
37,035 |
224,368 |
McKelligon Brian | President and CEO |
Dec 19 '23 |
Option Exercise |
0.30 |
7,500 |
2,272 |
160,063 |
McKelligon Brian | President and CEO |
Dec 19 '23 |
Sale |
4.48 |
7,500 |
33,566 |
152,563 |
McKelligon Brian | President and CEO |
Dec 12 '23 |
Option Exercise |
0.30 |
7,500 |
2,272 |
160,063 |
McKelligon Brian | President and CEO |
Dec 12 '23 |
Sale |
4.25 |
7,500 |
31,871 |
152,563 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):